Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

It's one of many changes Bayer CEO Bill Anderson has made. Still, the company's stock price this year has struggled.

The JV will focus on discovering and developing new drugs for conditions including haemophilia, heart disease in infants and a form of blindness called Stargardt. Bayer is just the latest in a ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Bayer (BAYZF) (BAYRY) says elinzanetant, its experimental therapy for hot flashes, reached the main goals in a late-stage ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bayer AG reported positive results for elinzanetant ... The German company’s drug met all the goals of a late-stage study for the treatment of moderate to severe vasomotor symptoms, also known ...